Appointment Targeting Next Steps to Increasing Shareholder Value
Aug. 20, 2013
/PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF), a life sciences company developing and commercializing high‐value cancer diagnostic tests, today announced the appointment of Mr.
as Senior Advisor to the Company effective
September 1, 2013
. Mr. Bordeleau will act as an executive in residence and report directly to DiagnoCure's board of directors. In collaboration with Company management, Mr. Bordeleau's initial mandate will be to identify and implement short term actions aimed at increasing shareholder value, and also to evaluate mid to long term scenarios optimizing corporate value.
Mr. Bordeleau joins DiagnoCure, following a highly successful international career in the life sciences industry. During his term as President of Atrium Innovations from 2000 to 2007, the company experienced sustainable double-digit organic growth through direct sales combined with international license and distribution agreements, augmented by multiple accretive acquisitions in
. Mr. Bordeleau also more recently contributed to the growth of BioCad Medical, positioning the company as a leader in CADCAM dentistry. BioCad Medical was purchased by Nobel Biocare 18 months after he joined the company. Mr. Bordeleau currently manages investments in start-up companies together with members of Anges Quebec, a network of business angels where he initiated investments in life sciences as responsible of the health and well-being sector.
"We are extraordinarily pleased that Mr. Bordeleau will be joining the DiagnoCure team. His strong track record of growing companies and creating value for shareholders is a powerful testament to his strength in successfully negotiating and closing international licensing and distribution agreements, and implementing value-creating acquisitions," said Dr.
, Chairman of the Board.
"Reporting directly to the Board, Mr. Bordeleau's business acumen will complement the scientific strengths of DiagnoCure's management team and the clinical insight of our Chairman. The board has given Richard significant powers to act as executive in residence in the creation of both a long-term vision for success and a short-term improvement of shareholder value," added Dr.
, DiagnoCure's Lead Director.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage
GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on PCA3 to Gen‐Probe, now a wholly‐owned subsidiary of Hologic Inc., operating as Hologic Gen‐Probe, for the development and commercialization of a prostate cancer test, DiagnoCure's proprietary molecular biomarker. Hologic Gen‐Probe's PROGENSA® PCA3 test is commercialized in
under CE mark and is approved for commercialization in
the United States
. For more information, please visit
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.